On February 18, the Hubei Provincial Science and Technology Innovation Conference was held in Wuhan, the event, first of its kind, "Scientists Hit the Red Carpet" was held before the conference. Professor Ma Ding, academician of the Chinese Academy of Engineering and director of the Department of Obstetrics and Gynecology of Tongji Hospital, was invited to hit the red carpet as one of the 16 representatives of Hubei scientists.
At the conference, the 2020 Hubei Science and Technology Awards were officially announced, and a total of 327 awards were awarded. Tongji Hospital, as the first author, has won 11 Hubei Provincial Science and Technology Progress Awards, among which included 2 first prizes, 4 second prizes, and 1 third prize. As a cooperative unit, it won 1 second prize and 3 third prizes.
The project of "Key Technology Innovation and Clinical Application in the Diagnosis and Treatment of Erectile Dysfunction(ED)" hosted by the team of Professor Liu Jihong of Urology won the first prize. Professor Liu Jihong and his team has been working hard for nearly 30 years and has achieved a series of breakthroughs in the field of ED, namely, precise diagnosis of its cause, research and development of new drugs, innovation of surgical methods, independent research and development of key surgical equipment, and industrialization. The results of this project have been identified as the internationally leading level and included in the diagnosis and treatment guidelines, which has comprehensively promoted the level of clinical diagnosis and treatment of ED and the development of the discipline in China.
The project "Innovative Research and Clinical Application of Hepatocellular Carcinoma Surgical Treatment Strategies" hosted by the team of Professor Zhang Bixiang of Liver Surgery also won the first prize. This research based on the work of academicians Qiu Fazu and Chen Xiaoping of Tongji Hospital closely meets the needs of patients. After more than 20 years, the team has proposed a variety of new concepts and new methods for clinical surgical treatment of liver cancer, and optimized the perioperative period of liver resection. The treatment plan improves the safety of surgery and reduces postoperative complications; pioneered a minimally invasive treatment system for liver cancer with robotic liver resection as the core and promotes the translational research of liver cancer from bench to bedside in China. Their team pioneered the use of Huai’er Granules as adjuvant treatment for patients after liver cancer surgery, which has been recommended and adopted by many guidelines in China. In addition, Professor Zhang Bixiang’s team is also committed to the research on ruptured hepatocellular carcinoma, and for the first time proposed the best time for staging surgery, which was evaluated by Academician Liu Yunyi as a major progress in the field of ruptured hepatocellular carcinoma!
In addition, the team of Professor Lei Ting’s from Neurosurgery (Project name: Technical Innovation of Minimally Invasive Surgery for Pituitary Adenomas and the Establishment of Precision Treatment Strategies), the team of Professor Xiang Hongbing from the Department of Anesthesiology (Project name: The Precise Positioning of New Sub-regions of Important Neuronuclei in the Brain Network and its Application Innovations), Professor Lu Fu'er’s team from the Department of Traditional Chinese Medicine (Project name: Technology and Clinical Application Innovation of Coptis and Its Components in the Treatment of Type 2 Diabetes) , and the Chief Pharmacist Liu Dong and his team of the Department of Pharmacy’"(Project name: Innovation and Application of the Clinical Value of Cultivating Bezoar in Vitro) were awarded the second prize of the Hubei Provincial Science and Technology Progress Award. Professor Zhen Hongtao’s team from the Department of Otolaryngology (Project name: Navigation-Assisted Transnasal Endoscopic Skull Base Minimally Invasive and Precision Surgery Series) won the third prize.
